Capivasertib Shortage Update: What Patients Need to Know in 2026

Capivasertib Shortage Update: What Patients Need to Know in 2026

If you take Capivasertib (brand name Truqap) for breast cancer, you may have heard about drug shortages affecting oncology medications. Naturally, you might be wondering: Is Capivasertib in shortage right now? Can I still get my prescription filled?

This article provides a current update on Capivasertib availability in 2026, explains why patients are experiencing difficulty finding it, and outlines practical steps you can take to stay on your treatment.

Is Capivasertib Still in Shortage?

As of early 2026, Capivasertib (Truqap) is not listed on the FDA Drug Shortage Database. This means there is no official, widespread manufacturing shortage of the drug.

However, many patients report difficulty getting their prescriptions filled. This is a common situation with newer, high-cost specialty oncology drugs — the medication is technically available, but access barriers make it feel like a shortage. The challenges are real, even if the cause is different from a traditional manufacturing shortage.

For background on why this happens, read our explainer: Why is Capivasertib so hard to find?

Why Is Capivasertib Hard to Find?

Several factors create access hurdles for patients:

Specialty Pharmacy Distribution

Capivasertib is only available through specialty pharmacies — not your local retail pharmacy. This limits where you can fill your prescription and adds processing time.

Prior Authorization Requirements

Nearly all insurance plans require prior authorization before covering Truqap. Your oncologist must submit documentation confirming your diagnosis, tumor mutations (PIK3CA, AKT1, or PTEN), and prior treatment history. This process can take days to weeks.

Companion Diagnostic Testing

You must have an FDA-approved companion diagnostic test (such as FoundationOne CDx) showing that your tumor has the required gene alterations. Waiting for test results adds time before treatment can even begin.

Insurance Denials and Appeals

Some patients face initial insurance denials, particularly if documentation is incomplete or the plan has strict step therapy requirements. Appeals are possible but add further delay.

How Much Does Capivasertib Cost in 2026?

The cash price of Capivasertib is approximately $23,762 per 28-day cycle (64 tablets). This makes it one of the more expensive oral oncology medications on the market.

For commercially insured patients, out-of-pocket costs vary widely depending on your plan. Many patients are eligible for the Truqap Co-Pay Savings Program, which can reduce monthly costs to as little as $0.

If you're uninsured or underinsured, the AZ&Me Prescription Savings Program may provide Truqap at no cost. For a complete breakdown of savings options, see our article on how to save money on Capivasertib in 2026.

Are There New Options for Patients in 2026?

The treatment landscape for HR-positive, HER2-negative metastatic breast cancer continues to evolve. In addition to Capivasertib, several other targeted therapies are now available:

• Inavolisib (Itovebi) — a newer PI3Kα inhibitor approved in 2024 for PIK3CA-mutated breast cancer, used with Palbociclib and Fulvestrant
• Alpelisib (Piqray) — a PI3K inhibitor for PIK3CA-mutated breast cancer
• Elacestrant (Orserdu) — a SERD for ESR1-mutated breast cancer
• Everolimus (Afinitor) — an mTOR inhibitor with generic options available

If you're struggling to access Capivasertib, one of these alternatives may be appropriate for your situation. Learn more in our guide to alternatives to Capivasertib.

How to Find Capivasertib in Stock

Here are the most effective steps you can take right now:

1. Use Medfinder

Medfinder helps you identify specialty pharmacies that have Capivasertib available. Search for "Truqap" or "Capivasertib" and see real-time availability near you.

2. Contact AstraZeneca Access 360

AstraZeneca's dedicated support program helps with everything from finding a pharmacy to navigating insurance. Call 844-275-2360 or visit MyAccess360.com.

3. Ask Your Oncologist for Help

Your cancer care team can expedite prior authorizations, appeal insurance denials, and coordinate with specialty pharmacies. Don't hesitate to ask for support — this is a normal part of accessing specialty medications.

4. Plan Ahead for Refills

Request refills at least 7–10 days in advance to allow for specialty pharmacy processing. Confirm that your prior authorization is still valid before each cycle.

For a full guide with step-by-step tips, read how to find Capivasertib in stock near you.

Final Thoughts

Capivasertib is not in a traditional drug shortage in 2026, but the access challenges patients face are real and frustrating. Between specialty pharmacy requirements, insurance prior authorizations, genetic testing, and high costs, getting your prescription filled can take time and persistence.

The most important thing is to not delay your treatment. Use the resources available to you — Medfinder, AstraZeneca Access 360, and your oncology team — to stay on track. And if Capivasertib isn't accessible right now, talk to your oncologist about whether an alternative therapy might be right for you in the meantime.